Citations

Clear

13603 citation(s) found for "_, _".

Artificial intelligence, machine learning, telemedicine, and digital transformation in nephrology and transplantation
Thongprayoon, Charat, Cheungpasitporn, Wisit, Cheungpasitporn, Wisit , Cheungpasitporn, Wisit , Thongprayoon, Charat , Wathanavasin, Wannasit

Mayo Clinic

Renal Failure | October 20, 2025 | Volume: 47 | Issue: 1 | Pages: No page available

10.1080/0886022x.2025.2574537 | PMID 41111231 Get It

Novel SMARCA2 :: DDIT3 Fusion in Primary Subcutaneou
Shah, Ahmed , Sukov, William R. , Halling, Kevin C. , Marcelis, Lukas , Oliveira, André M. , Shah, Ahmed , Halling, Kevin, Oliveira, Andre, Shah, Ahmed

Mayo Clinic

Genes, Chromosomes and Cancer | October 18, 2025 | Volume: 64 | Issue: 10 | Pages: No page available

10.1002/gcc.70089 | PMID 41108625 Get It

ABSTRACT Myxoid liposarcoma (MLS) accounts for 20%–30% of all liposarcomas, with most cases harboring the fusion gene FUS::DDIT3 , while approximately 5% exhibit the EWSR1::DDIT3 fusion. We report the case of a 26‐year‐old male patient with a right upper arm mass. The tumor displayed the classic histological features of MLS, including small spindle/ovoid cells, variable univacuolated lipoblasts, and a prominent myxoid stroma with delicate arborizing vasculature. Despite these characteristic features, fluorescence in situ hybridization (FISH) revealed no apparent rearrangement of the DDIT3 locus. Next‐generation sequencing (NGS) identified a novel fusion transcript in which SMARCA2 exon 4 was fused in‐frame with DDIT3 exon 2. Chromosomal microarray analysis demonstrated the unbalanced nature of the rearrangement, with partial deletions of 0.243 and 0.176 Mb flanking the centromeric end of the DDIT3 locus on 12q13.3 (which also included GLI ) and disrupting the SMARCA2 locus on 9p24, respectively. The resultant chimeric fusion protein is predicted to lack the SMARCA2 DNA‐binding domains while retaining the DDIT3 leucine zipper dimerization domain. These findings indicate an unusual and complex rearrangement, leading to the recruitment of a novel DDIT3 partner gene. Moreover, they emphasize that the functional aspects of myxoid liposarcoma fusion genes depend on the retention of the key DDIT3 domain. Finally, this case illustrates how classic morphology can appropriately trigger reflex molecular analyses, which may, in turn, uncover novel fusion genes or other molecular alterations.
Robotic-Assisted Vascular Surgery: Current Landscape, Challenges, and Future Directions
Alsabbagh, Yaman , Jlilati, Adeeb , Sarmiento, Joaquin, Jacobs, Christopher R. , Elli, Enrique F. , Farres, Houssam , Jlilati, Adeeb , Jacobs, Christopher, Farres, Houssam , Erben, Young , Jacobs, Christopher

Mayo Clinic

Journal of Clinical Medicine | October 17, 2025 | Volume: 14 | Issue: 20 | Pages: 7353

10.3390/jcm14207353 | PMID 41156226 Get It

Vascular surgery has evolved from durable yet invasive open reconstructions to less traumatic endovascular techniques. While endovascular repair reduces perioperative morbidity, it introduces durability challenges and the need for lifelong surveillance. Laparoscopic surgery bridged some gaps but was hindered by steep learning curves and technical limitations. Robotic-assisted surgery represents a “third revolution”, combining the durability of open repair with the recovery and ergonomic benefits of minimally invasive approaches through enhanced 3D visualization, wristed instrumentation, and tremor filtration. This review synthesizes current evidence on robotic applications in vascular surgery, including aortic, visceral, venous, and endovascular interventions. Feasibility of robotic vascular surgery has been demonstrated in over 1500 patients across aortic, visceral, venous, and decompression procedures. Reported outcomes include pooled conversion rates of ~5%, 30-day mortality of 1–3%, and long-term patency rates exceeding 90% in aortoiliac occlusive disease. Similarly favorable outcomes have been observed in AAA repair, visceral artery aneurysm repair, IVC reconstructions, renal vein transpositions, and minimally invasive decompression procedures such as median arcuate ligament and thoracic outlet syndromes. Endovascular robotics enhances catheter navigation precision and reduces operator radiation exposure by 85–95%, with multiple series demonstrating consistent benefit compared to manual techniques. Despite these advantages, adoption is limited by high costs, lack of dedicated vascular instruments, absent haptic feedback on most platforms, and the need for standardized training. Most available evidence is observational and from high-volume centers, highlighting the need for multicenter randomized trials. Future directions include AI-enabled planning and augmented-reality navigation, which are the most feasible near-term technologies since they rely largely on software integration with existing systems. Other advances such as microsurgical robotics, soft-robotic platforms, and telesurgery remain longer-term developments requiring new hardware and regulatory pathways. Overcoming barriers through collaborative innovation, structured training, and robust evidence generation is essential for robotics to become a new standard in vascular care.
Leveraging Artificial Intelligence for the Diagnosis of Systemic Sclerosis Associated Pulmonary Arterial Hypertension: Opportunities, Challenges, and Future Perspectives
Jain, Samiksha , Kaur, Avneet , Qadeer, Abdul , Ghosh, Victor , Thota, Shivani, Banala, Mallareddy , Lee, Jieun , Yerrapragada, Gayathri, Poonguzhali, E. , Shariff, Mohammed Naveed , Natarajan, T.K. , Janarthanan, Jayarajasekaran, Kala, Jayavinamika Jayapradhaban, Richard, Samuel, Vommi, Saai Poornima, Karuppiah, Shiva Sankari, Muthyala, Anjani, Iyer, Vivek , Helgeson, Scott A. , Mitra, Dipankar , Arunachalam, Shivaram P. , Natarajan, Thangeswaran , Jayapradhaban Kala, Jayavinamika, Iyer, Vivek N , Arunachalam, S P , Helgeson, Scott A , Shariff, Mohammad Naveed , Qadeer, Abdul , Thota, Shivani

Mayo Clinic

Advances in Respiratory Medicine | October 17, 2025 | Volume: 93 | Issue: 5 | Pages: 47

10.3390/arm93050047 | PMID 41149139 Get It

Systemic sclerosis-associated pulmonary arterial hypertension (SSc-PAH) is a life-threatening vascular complication of SSc, marked by high morbidity and mortality. Early diagnosis remains a major challenge due to nonspecific symptoms and the limitations of conventional tools such as echocardiography (ECHO), pulmonary function tests (PFTs), and serum biomarkers. This review evaluates the emerging role of artificial intelligence (AI), particularly machine learning (ML) and deep learning (DL), in improving the diagnostic landscape of SSc-PAH. A comprehensive literature search was conducted across PubMed, Scopus, IEEE Xplore, Embase and Google Scholar to identify studies involving AI applications in SSc, pulmonary arterial hypertension (PAH), and their intersection. Evidence indicates that AI models can assist interpretation across modalities, including heart sounds, ECGs, chest X-rays (CXRs), ECHOs, CT pulmonary angiography (CTPA), and omics-based biomarkers. While several models show encouraging diagnostic performance, their accuracy varies by dataset and modality, and most require external validation against right heart catheterization (RHC)-confirmed cohorts. Integrating multimodal data through AI frameworks may enhance early recognition and individualized risk stratification; however, these tools remain exploratory. Future work should emphasize harmonized hemodynamic definitions, transparent validation protocols, and SSc-specific datasets to ensure clinical applicability and reproducibility.
Who improves, who doesn’t and why? Defining improvement and drivers of outcomes in pediatric MASLD
Harris, Kevin B. , Ilyas, Sumera I.

Mayo Clinic

Hepatology | October 17, 2025 | Volume: 82 | Issue: 5 | Pages: 1043-1044

10.1097/hep.0000000000001506 | PMID 41104550 Get It

Deep learning in CT image reconstruction and processing: techniques, performance evaluation, radiation dose, and future perspective
Yu, Lifeng , Chen, Guang‐Hong , Kachelrieß, Marc , Zeng, Rongping , Zhou, Zhongxing , Yu, Lifeng , Fletcher, Joel G. , Jiang, Lu

Mayo Clinic

British Journal of Radiology | October 16, 2025 | Volume: 98 | Issue: 1175 | Pages: 1775-1787

10.1093/bjr/tqaf260 | PMID 41099810 Get It

Abstract This article provides an overview of deep-learning–based techniques in CT image reconstruction and processing (referred to as “DLR”), covering technical implementations, performance evaluation, radiation dose reduction, and future perspectives. DLR methods can be categorized into projection-space, projection-to-image-space, image-space, and various hybrid techniques, with applications such as noise reduction, artefact correction, and spatial resolution enhancement. Performance evaluations include phantom-based studies, patient image-based studies, and virtual imaging trials. These evaluation studies demonstrated that DLR can effectively reduce image noise while preserving an image texture like in traditional filtered-backprojection (FBP) images, although the extent of radiation dose reduction varies widely depending on the study and the specific diagnostic task. Challenges remain in low-contrast lesion detection and characterization, where dose reduction may still be less than 50% compared to traditional reconstruction methods. Additionally, the potential for DLR methods to generate false structures or “hallucinations,” especially at low radiation doses, emphasizes the need for effective monitoring and mitigation strategies from both technical and clinical perspectives. Quantitative, accurate, and efficient evaluation techniques, such as virtual image trial-based methods, can be explored to help optimize these algorithms for reducing radiation dose and enhancing diagnostic performance.
Abstract TH290: Blood Pressure Trajectory and Treatment Patterns Among Older Patients with Apparent Treatment Resistant Hypertension: Insights from a Large, Community-Based Healthcare System
Mamprejew, Nicole, Abusulb, Ammar, Cubeddu, Robert, Kassar, Emily, Labovitz, Arthur, Orringer, Carl, Alvi, Mohammed Ali, Albaghdadi, Mazen, Mamprejew, Nicole, Abusulb, Ammar, Cubeddu, Robert, Kassar, Emily, Labovitz, Arthur, Orringer, Carl, Alvi, Mohammed Ali, Albaghdadi, Mazen

Mayo Clinic

Hypertension | October 16, 2025 | Volume: 82 | Issue: Suppl_1 | Pages: No page available

10.1161/hyp.82.suppl_1.th290 Get It

Background: Aging increases the risk of resistant hypertension which is associated with an increased risk of mortality and cardiovascular events. Here, we examined the characteristics, blood pressure (BP) trajectories, and treatment patterns of older patients with apparent treatment resistant hypertension (aTRH). Hypothesis: We hypothesized aTRH would be undertreated, especially in octogenarians. Methods: We conducted a retrospective study of all patients with two available ambulatory BP measurements separated by at least 3 months in a community-based teaching hospital. aTRH was defined as BP above goal despite the use of ≥3 antihypertensive medication classes or controlled BP on ≥4 antihypertensive medication classes. Results: Of the 71,470 patients with available data, 7308 (10.2%) met criteria for aTRH with a mean follow-up length of 18.9 months. Compared to patients with normal BP, patients with aTRH were older with a mean age of 74 years versus 65 years (p<0.001). Patients with aTRH were more likely to be males (58.3%) compared to the normal BP groups (40.6%, p<0.001) (Figure 1). Compared to patients with normal BP, patients with aTRH were more likely to be obese and have a higher prevalence of smoking history, diabetes, coronary artery disease, heart failure, peripheral arterial disease, atrial fibrillation, and chronic kidney disease (Figure 1). Amongst those with aTRH, 1566 (5.3%) were aged 18-65, 3763 (13.2%) were aged 66-79, and 2623 (19.7%) were ≥80 years old. At follow-up, among those with aTRH at baseline, 5773 (72.6%) remained with aTRH, 896 (11.3%) improved to non-aTRH, 1270 (16.0%) improved to controlled BP, and 13 (0.2%) improved to normal BP (Figure 2). Most patients irrespective of age had no change in the number of medications at follow-up; only 15.5% of octogenarians with aTRH had an increase in antihypertensives (Figure 3). Between baseline and follow up, octogenarians as a whole had a systolic BP drop of -2.34 (p<0.001), and diastolic BP drop of -0.56 (p=0.061), whereas octogenarians with aTRH had a systolic BP drop of -3.7 (p<0.001) and diastolic BP drop of -0.55 (p=0.050). Conclusion: In an ambulatory population of patients at a community hospital, the prevalence of aTRH was high among patients ≥80 years and associated with established cardiovascular risk factors. Most patients with aTRH do not have a change in BP status over time. Anti-hypertensive medication escalation is infrequent among patients with aTRH irrespective of age.
Abstract TH163: Persistence of Blood Pressure Reduction Following Renal Denervation Across Short, Medium, and Long Term Follow-Up
Rezasoltani, Mahsa , Namin, Sara Montazeri , Eshraghi, Reza , Bahrami, Ashkan , noroozi, matin, Akbari, Touba, Behbudi, Fatemeh, Mandegar, Mohammad Hossein , Yazdani, Mohammad Sepehr, Pirdehghan, Reza , Shahid, Farhan , Ebrahimi, Pouya , Namazi, Mohammad Javad , Moradi, Ali, noroozi, matin, Akbari, Touba, Yazdani, Mohammad Sepehr, Ahmed, Raheel

Mayo Clinic

Hypertension | October 16, 2025 | Volume: 82 | Issue: Suppl_1 | Pages: No page available

10.1161/hyp.82.suppl_1.th163 Get It

Introduction: Resistant and uncontrolled hypertension pose persistent clinical and public health challenges. Renal denervation, a catheter-based procedure targeting renal sympathetic nerves, has emerged as a promising approach to lower blood pressure by reducing sympathetic overactivity. Hypothesis: A systematic review and meta-analysis of sham-controlled trials investigated whether renal denervation results in sustained blood pressure reduction across short-, medium-, and long-term follow-up. Methods: We searched PubMed, Embase, CENTRAL, and Web of Science through March 2025. The protocol was registered in PROSPERO (CRD420251015937). Randomized, sham-controlled trials of renal denervation in resistant/uncontrolled hypertension were included. Primary outcomes were ambulatory blood pressure (daytime, nighttime, and 24-hour); secondary outcomes included office and home blood pressure measurements. Follow-up durations were categorized into three groups: less than 6 months, 6–12 months, and greater than 12 months. Risk of bias was assessed using RoB-2. Results: Twenty trials (25 reports) with 2,167 RDN patients and 1,744 sham controls were included. Most trials had a low risk of bias. RDN significantly reduced 24-hour SBP (–3.29 mmHg, 95% CI: –5.91 to –0.67) and DBP (–1.42 mmHg, 95% CI: –2.29 to –0.55), despite high heterogeneity (I2 > 90%). Daytime DBP showed a significant reduction (–2.90 mmHg, 95% CI: –4.39 to –1.41), while other BP measures were less consistent. Home SBP was significantly reduced (–5.04 mmHg, 95% CI: –8.50 to –1.58). At 6–12 months, 24-hour SBP reduction persisted (–3.36 mmHg, 95% CI: –5.71 to –1.01), but DBP effects were nonsignificant. Long-term follow-up revealed nonsignificant changes in systolic blood pressure and diastolic blood pressure. Conclusions: Renal denervation modestly lowers BP in the short term (<6 months). Mid-term SBP reduction persists, but diastolic and long-term effects are inconsistent. These findings highlight the need for refined patient selection, optimized techniques, and longer follow-up trials.
Implantable cardioverter defibrillators for long QT syndrome and catecholaminergic polymorphic ventricular tachycardia? (Not so fast, Louis)
Schwartz, Peter J. , Ackerman, Michael J. , Schwartz, Peter J.

Mayo Clinic

Europace | October 16, 2025 | Volume: 27 | Issue: 11 | Pages: No page available

10.1093/europace/euaf266 | PMID 41108755 Get It

Abstract Few medical decisions have a greater impact on the life of patients affected by either long QT syndrome (LQTS) or catecholaminergic polymorphic ventricular tachycardia (CPVT) as the one to recommend an implantable cardioverter defibrillator (ICD) or not. If the decision is correct, a life might be saved or a litany of ICD-related complications might be avoided. If it is wrong, well you can fill in the blanks. Many physicians take the fastest and simplest road by recommending an ICD which represents ‘double protection’: for the patients and for themselves. Our opinion is that this requires a very careful consideration about the pros and cons and should be taken neither lightly nor quickly. Moreover, there is another side to this moon, which also requires more thought than usually assumed. As to LQTS and CPVT, the current data strongly indicate that when high risk patients are treated with either combination drug therapy comprising beta blockers and mexiletine (LQTS) or beta blockers and flecainide (CPVT) or triple therapy with left cardiac sympathetic denervation as the treatment intensifier, mortality is close to zero and most patients have no life-threatening events. Thus, we stand by our view that most patients still do not need and should not receive an ICD. However, sometimes patients are desperately worried for the fear of dying suddenly and ask for an ICD despite being at low risk. Their request should be listened to, respected, and considered with empathy because immortality cannot be guaranteed. We believe that both expertise and compassion are quintessential to practicing the science and art of medicine.
Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials
Giblin, K., Kaplan, Lee M. , Somers, Virend K., Roux, Carel W. le , Hunter, David J. , Lalonde, Amy , Bethel, M. Angelyn , Hunter, David J. , Giblin, Kathryn , le Roux, Carel W , Somers, Virend K. , Wu, Qiwei , Ahmad, Nadia Y.

Mayo Clinic

Diabetes, Obesity and Metabolism | October 15, 2025 | Volume: 28 | Issue: 1 | Pages: 83-93

10.1111/dom.70209 | PMID 41090431 Get It

Abstract Aims Retatrutide, a novel synthetic molecule, is a triple agonist activating the glucose‐dependent insulinotropic polypeptide, glucagon‐like peptide‐1 and glucagon receptors. The TRIUMPH clinical development program evaluates its safety and efficacy concurrently for the treatment of obesity and two related complications—obstructive sleep apnea (OSA) and knee osteoarthritis (OA). A novel basket trial design simultaneously evaluates retatrutide treatment across these multiple adiposity‐related disease states. Materials and methods TRIUMPH consists of four Phase 3, multicenter, randomized, double‐blind studies assessing weekly subcutaneous retatrutide compared to placebo, in conjunction with healthy diet and physical activity in over 5800 participants. The four trials consist of two weight management basket trials (TRIUMPH‐1 and TRIUMPH‐2) with OSA and/or OA protocols nested within the weight management trial; one weight management trial in a population with CVD (TRIUMPH‐3); and one stand‐alone OA trial (TRIUMPH‐4). The primary endpoint for weight management is percent change in body weight, for OSA is change in Apnea‐Hypopnea Index and for knee OA includes change in the Western Ontario and McMaster Universities Osteoarthritis Index pain subscale score. The basket trial permits independent analysis of weight management, OSA and OA studies with type I error rate controlled at α = 0.05, split between the overarching weight management and each basket trial. Conclusions By recruiting participants with shared disease exposures, the TRIUMPH program will assess the safety and efficacy of retatrutide for the treatment of adults with obesity and two of its common complications—OSA and OA.